Sanai FM, et al. - Physicians designed this study to evaluate real-world safety and efficacy of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) in hepatitis C genotype (GT) 4 and 1–infected patients with severe chronic kidney disease (CKD). Amongst GT4 and GT1 patients with CKD stages 4-5, a 12-week regimen of OBV/PTV/r ± DSV with or without RBV was highly effective with a favourable safety profile. Regardless of patient characteristics, SVR12 rates were high.